pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of subjects

Characteristics Hypothyroid (n=86) Euthyroid (n=70) p
Age ≥65, n (%) 33 (38.4) 30 (42.9) 0.62
Male, n (%) 60 (69.8) 61 (87.1) 0.01
BMI (kg/m2) ≥25, n (%) 19 (22.9) 16 (24.6) 0.93
Heng risk criteria, n (%) 0.406
Favorable 16 (18.6) 18 (25.7)
Intermediate 58 (67.4) 40 (57.1)
Poor 12 (14.0) 12 (17.1)
Past nephrectomy, n (%) 75 (87.2) 60 (85.7) 0.82
Clear cell histology, n (%) 85 (95.3) 66 (94.3) 1.00
≥2 metastatic sites, n (%) 52 (60.5) 44 (62.9) 0.87
Lung metastasis, n (%) 61 (70.9) 53 (75.7) 0.59
Liver metastasis, n (%) 11 (12.8) 11 (15.7) 0.65
Bone metastasis, n (%) 20 (23.3) 18 (25.7) 0.85
Past systemic therapy, n (%) 22 (25.6) 19 (27.1) 0.86
Underlying HTN, n (%) 54 (37.2) 44 (37.1) 1.00
Underlying CKD, n (%) 15 (17.4) 14 (20.0) 0.68
Underlying proteinuria, n (%) 15 (17.4) 12 (17.1) 1.00
LDH >ULN, n (%) 2 (4.2) 2 (6.5) 0.64
Serum calcium >ULN, n (%) 7 (8.1) 11 (15.7) 0.21

BMI: body mass index, CKD: chronic kidney disease; HTN: hypertension, LDH: lactate dehydrogenase, ULN: upper limit of normal

Korean J Clin Pharm 2024;34:184-93 https://doi.org/10.24304/kjcp.2024.34.3.184
© 2024 Korean J Clin Pharm